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1. INTRODUCTION 
Cancer is a major public health problem worldwide. Currently, after cardiovascular 
diseases, cancer is the second leading cause of death in European countries.  
Approximately 40 % of cancer patients can be treated surgically, and the great majority 
of patients need chemotherapy. Although a number of anticancer drugs have been 
commercialized, the need for more effective ones continues to exist, because the most 
common tumours are resistance to available drugs. 
 
1.1 Cellular drug resistance mechanisms  
The ability of cancer cells to become cross-resistance to structurally and functionally 
unrelated anticancer drugs is known as multidrug resistance (MDR). It has been 
recognized that MDR is multifactorial and factors that affect response to anticancer 
chemotherapy include cell kinetic, pharmacokinetic and cellular drug resistance 
mechanisms. Cellular mechanisms are categorized in terms of alterations in the 
biochemistry of malignant cells: 
I. Non-classical MDR phenotypes 
 Drug resistance mediated by detoxification mechanism of the drug in the cells 
 Alterations of drug targets or enhancement of target repair 
 Defective apoptotic pathways 
II. Transport-based classical MDR phenotypes 
 Overexpression of ATP-binding cassette (ABC) transporters  
 
1.2 ABC transporters 
The ABC transporter superfamily is among the largest and most broadly expressed 
protein superfamilies known. ABC transport proteins that have been implicated in 
multidrug resistance include the 170 kDa multidrug resistance protein 1 (MDR1) also 
called P-glycoprotein (P-gp); the 190 kDa multidrug resistance protein 1 (MRP1); the 
breast cancer resistance protein (BCRP) and the lung resistance protein (LRP), 
also known as the major vault protein. LRP is not an ABC transporter but it is frequently 
expressed at high levels in drug-resistant cell lines and tumour samples. These ABC 
transporters serve to pump anticancer drugs out of the cells, resulting in lack of 
intracellular levels of drug necessary for effective therapy. 
Although these transporters have been identified as drug-resistance proteins, they are all 
expressed in normal tissues important for absorption (e.g., lung and gut) metabolism and 
elimination (liver and kidney). In addition, they have an important role in maintaining the 
barrier function of sanctuary site tissues (e.g. blood–brain barrier). 
 
1.3 Substrates and modulators of ABC transporters 
ABC transporters recognize a very large range of drug substrates; include a large 
number of anticancer drugs (anthracyclines, Vinca alkaloids, epipodophyllotoxins, 
taxanes). Recognized substrates are mostly hydrophobic compounds, but MDR pumps 
are also capable to extrude a variety of amphipathic anions and cations.  
 
Many of the first generation chemosensitizers (e.g. verapamil, cyclosporine A) were 
themselves substrates for P-gp and competed with the cytotoxic drugs for efflux by the 
P-gp pump. Therefore, high serum concentrations of these agents were needed to 
produce sufficient intracellular concentration. At these elevated doses, compounds 
exhibited severe and sometimes life-threatening toxicities. 
The second generation modulators (e.g. dexverapamil, dexniguldipine, valspodar, 
biricodar) exhibited decreased inherent toxicity while retaining MDR reversal efficacy, but 
they also retain some characteristics that limit their clinical usefulness. Many of these 
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MDR modulators are also substrates for cytochrom P450 3A4 and metabolized by this 
enzyme or inhibited several other ABC transporters. 
Third generation agents specifically and potently inhibit P-gp and do not inhibit other 
ABC transporters. Clinical trials with these new third generation agents (e.g. tariquidar, 
laniquidar zosuquidar) are ongoing with the aim for a longer survival in cancer patients. 
This effort continues, but none of them has found a general clinical use so far. 
 
1.4 The oncomodulatory effect of human cytomegalovirus  
Studies indicated that, the human cytomegalovirus (CMV) infection might be associated 
with the pathogenesis of several human malignancies. CMV infection modulates 
properties of tumour cells such as growth, apoptosis, production of angiogenic factors, 
cell invasion and immunogenic properties. CMV infections fail to transform susceptible 
normal human cells. 
The oncomodulatory effects are mediated mainly by the activity of CMV regulatory 
proteins. Immediate early (IE) antigen expression is based on the appearance of the 
respective mRNA or protein and rely on the persistence of viral infection in malignant 
cells. Both latent infection and reactivation are determined by the activity of IE gene 
products. IE gene products accumulate in infected cells causing disturbance of host cell 
functions.  
The development of strategies to inhibit human CMV IE antigen expression and/or 
function can be an important goal to prevent and treat certain forms of cancers 
associated with human CMV. 
 
 
2 .  A I M S  O F  T H E  ST U D Y  
 
In spite of the great number of MDR modulators known, no effective inhibitor without side 
effects is still available for clinical practice. Our purpose was to find MDR reversal agents 
less toxic than verapamil among various synthetic and some naturally-occurring plant 
derived compounds. 
The effect of selected MDR reversal compounds were studied in combination with 
anticancer chemotherapeutics both in vitro and in vivo. Apoptosis induction and inhibition 
of tumour promotion were studied as well. 
 
Main goals of the study in details: 
I. Antiproliferative and cytotoxic effect of tested compounds 
Before starting the multidrug resistance studies the antiproliferative and cytotoxic 
properties of the compounds were determined and compared on various cell lines 
II. Reversal of MDR1 by flow-cytometric assay 
1. Reversal of multidrug resistance on human mdr1 gene-transfected mouse 
lymphoma cell line (L 5178 Y) by various compounds (cinnamylidene ketones, 
1,4-diphenyl-1,4-dihydropyridines, phenothiazines, HSP90 inhibitor peptide 
derivatives and Betti base derivative of Tylosin)  
2. MDR1 reversal effect of cinnamylidene ketones, 1,4-diphenyl-1,4-
dihydropyridines, phenothiazines and certain Euphorbia diterpenes on human 
colon cancer cells (COLO 320) 
III. Interaction of resistance modifiers with anticancer drugs 
1. Antiproliferative effect of the combination of some representative resistance 
modifiers and some group representative anticancer drugs (doxorubicin, 
epirubicin, paclitaxel, vincristine) were examined by checkerboard microplate 
method in vitro 
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2. To investigate the in vivo P-glycoprotein inhibition of the most effective MDR-
reversal Betti base derivative, N-tylosil aminonaphtol (TBN), DBA/2 mice were 
used bearing syngenic resistance T-cell lymphoma L 5178 Y. The doxorubicin 
accumulation in tumour in the presence or absence of modulator was 
compared with in vitro results 
IV. Apoptosis induction of some resistance modifiers 
1. As an alternative means of citotoxic effects, programmed cell death induction 
was studied of the most effective resistance modifiers by flow cytometry using 
human mdr1 gene-transfected mouse lymphoma cells 
2. Analysis of apoptotic events by staining with ethidium bromide and acridine 
orange, on human cervical adenocarcinoma cell line (HeLa) was also 
examined in the presence of one representative jatrophane diterpene 
V. Anti-promotion effect of plant derivatives 
To search for antitumour promoters from plants sources, the effect of some 
macrocyclic lathyrane-type diterpenoids, were studied on the expression of human 
cytomegalovirus immediate-early (IE) antigen in human lung cancer cells  
 
3 .  M AT ER I AL S  AN D  M ET H O D S  
 
3.1 Chemicals 
 
Synthetic compounds 
Sixteen cinnamylidene derivatives (1-16); forty-one substituted 1,4-diphenyl-1,4- 
dihydropyridines (DL1-20 and DP70-90); seven phenothiazine derivatives: 
Perphenazine (Bracco-Italy), promethazine hydrochloride (EGYT-Hungary), 
oxomemazine (Rhone-Poulence-France), methotrimeprazine maleate (EGYTE-
Hungary), trifluoropromazine hydrochloride (Squibb-England), trimeprazine (Rhone-
Poulence-France), prochlorperazine dimaleate (Farmitalia); ten Heat Shock Protein 90 
(HSP90) inhibitor peptide derivatives: D-Trp-Phe-D-Trp-Leu-AMB (1), p-HOPA-D-Trp-
Phe-D-Trp-Leu-ψ(CH2NH)-Leu-NH2 (2), D-Trp-Phe-D-Trp-OH (3), Suc-D-Trp-Phe-D-Trp-
Leu-AMB (4), D-Tyr-Phe-D-Trp-Leu-AMB (5), D-Arg-D-Trp-Phe-D-Trp-Leu-Leu-NH2 (6), 
Leu-ψ(CH2NH)-Leu-NH2x2HCl (7), Phe-Trp-Phe-Trp-Leu-Leu-NH2 (8), Tyr-Trp-Phe-Trp-
Leu-Leu-NH2 (9) and Tyr-D-Trp-Phe-D-Trp-Leu-Leu-NH2 (10);  N-tylosil-1-α-amino-(3-
bromophenyl)-methyl-2-naphthol (TBN);  
 
Natural compounds 
Nine Euphorbiaceae diterpenes: The compounds were isolated from the lipophilic 
phase of methanol extracts of Euphorbia esula (compounds 1, 2 and 3), E. peplus 
(compounds 4 and 5), E. villosa (compound 6) and E. serrulata (compound 7, 8 and 9); 
Six macrocyclic lathyrane-type diterpenes: Compounds were isolated from the 
methanol extract of Euphorbia lagascae (latilagascene A (1), latilagascene B (2), 
latilagascene C (3), latilagascene D (4), latilagascene E (5), jolkinol B (6); 
 
Other chemicals were used in in vitro assays: 
Verapamil (EGIS, Hungarian Pharmaceutical Company, Budapest, Hungary); 
phosphate-buffered saline  and dimethyl sulfoxide (PBS and DMSO; Sigma-Aldrich Ltd., 
Budapest, Hungary); 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, 
sodium dodecyl sulphate and Rhodamin 123  (MTT, SDS and R123; Sigma, St Louis, 
MO, USA); Doxorubicin hydrochloride (Wako Pure Chem, Ind, Osaka, Japan); epirubicin 
hydrochloride (Farmitalia Carlo Erba, Milano, Italy); Annexin-V-FITC (Annexin-V; human 
recombinant-FITC; Alexis Biochemical, Grünberg, Germany); propidium iodide and 
ethidium bromide/acridine orange (PI and EB/AO; Sigma-Aldrich Ltd., Budapest, 
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Hungary); monoclonal antibody (MAB810; Chemicon International Inc., Temecula, CA, 
USA); fluorescein isothiocyanate (FITC)-conjugated rabbit anti-mouse IgG (Sigma-
Aldrich Ltd., Budapest, Hungary);  
 
The following compounds were used in in vivo assays: 
Natrium-pentobarbital (Nembutal, Cave-Sante Animale, Brussels); Doxorubicin HCl and 
daunorubicin HCl were purchased as a powder for injection from Teva Pharma (Wilrijk, 
Belgium) and Aventis Pharma (Brussels, Belgium); water was purified by the Milli-Q 
system (Millipore, Milford, USA) and acidified water was prepared by the addition of 
perchloric acid Sigma –Aldrich (Steinheim, Germany); 
 
3.2 Cell cultures  
3.2.1 The L 5178 Y mouse T-cell lymphoma cells (transfected with pHa 
MDR1/A retrovirus) 
3.2.2 The human colon cancer cells (COLO 320)  
3.2.3 The  human cervical adenocarcinoma cells (HeLa)  
3.2.4 The human lung alveolar epithelial cells (A549)  
3.2.5 Normal human lung fibroblast (MRC 5)  
The cell lines were incubated in a humified atmosphere (5% CO2, 95% air) at 37 °C. The 
semiadherent human cancer cells were detached with 0.25% trypsin and 0.02% EDTA 
for 5 min at 37 °C. 
 
3.3  Animals 
DBA/2 inbred mice (female, 5-7 weeks old) were obtained from Charles River Laboratory 
(France). All aspects of the animal experiment and husbandry were carried out in 
compliance with national and European regulations and were approved by the Animal 
Care and Use Committee of K. U. Leuven.  
3.4 Virus 
The stock of human CMV laboratory-adapted strain “Towne” was propagated in confluent 
MRC-5 cells grown in RPMI medium supplemented with 10% FCS and antibiotics. The 
infectivity titer was determined by plaque assay with the inoculation of confluent MRC 5 in 
24 well plates. 
 
3.5 Assay for antiproliferative and cytotoxic effect 
The effects of increasing concentrations of the drugs alone on cell growth were tested in 
96-well flat-bottomed microtiter plates. The compounds were diluted from high to low 
concentrations horizontally in the plates. Cells were seeded into each well 
(1×104 cell/well)) with the exception of the medium control wells. The plates were 
incubated at 37 °C for 72 h, (in case of cytotoxicity test the cell number were 3×104 /well 
and the incubation time was 48 h) and 15 µL of MTT solution (from a 5 mg/mL stock) 
was then added to each well. After incubation at 37 °C for 4 h, 100 µL of SDS solution 
(10%) was measured into each well. The plates were further incubated at 37 °C 
overnight to allow the dissolution of formazan crystals produced by the mitochondrial 
enzymes of living cells. The extend of inhibition of cell proliferation was determined by 
measuring the optical density (OD) of the chromogenic products at 550 nm (ref. 630 nm) 
with a Dynatech MRX vertical beam ELISA reader (Labsystems, Helsinki, Finland). 
Inhibition of cell growth (as a percentage) was determined according to the formula, in 
which OD cell control means the untreated cells: 
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3.6 Flow-cytometric assay for R123 accumulation in tumour cells 
The cells were adjusted to a density of 2×106/mL, resuspended in serum-free medium 
and distributed in 0.5 mL aliquots into Eppendorf centrifuge tubes. The tested 
compounds were added at various concentrations in different volumes, from the 1.0-10.0 
mg/mL stock solutions and the samples were incubated for 10 min at room temperature. 
Next, 10 µL (5.2 µM final concentration) of the indicator R 123 was added to the samples 
and the cells were incubated for a further 20 min at 37 °C, washed twice and 
resuspended in 0.5 mL PBS for analysis. The fluorescence of the cell population was 
measured with a Beckton Dickinson FACScan instrument (cell sorter, Oxford, 
U.K.).Verapamil was used as a positive control.  
The fluorescence activity ratio (FAR) was calculated, on the basis of the measured 
fluorescence intensities (FL1): 
 
cellsuntreatedFL
cellstreatedFL
FAR
1
1
=
 
3.7 Checkerboard microplate methods as a model for combination therapy 
It was applied to study the effects of drug interactions between resistance modifiers and 
cytotoxic compound on cancer cells. The dilutions of anticancer drug were made in a 
horizontally and the dilutions of resistance modifiers vertically in the microtiter plate in 
100 µL volume. The cell suspension in the tissue culture medium was distributed into 
each well in 50 µL containing 1×104 cells. The plates were incubated for 72 h at 37 °C in 
a CO2 incubator. The cell growth rate was determined after MTT staining and the 
intensity of the blue colour was measured on a micro ELISA reader. Drug interactions 
were evaluated according to the following expressions: 
FICA = ID50A in combination / ID50A alone    
FICB = ID50B in combination / ID50B alone   
where ID is the inhibitory dose, and FIC is the fractional inhibitory concentration. 
The fractional inhibitory index, FIX = FICA + FICB, demonstrates the effect of the 
combination of the anticancer drug and the tested compound. It is accepted that, if the 
value of FIX is 0.51-1.00, it is an additive effect; if FIX is <0.50, it is a synergistic one; a 
FIX value in the interval 1.00-2.00 is considered an indifferent effect, while a value >2.00 
indicates an antagonistic effect. 
 
3.8 Cellular accumulation and cytotoxicity of doxorubicin in vitro 
Parental or transfected L5178 Y cells were plated using 24 well plates (4x106 cell/1.5ml 
per well) in serum-free medium. TBN (10µM) was added (or not) 30 min before exposing 
the cells to 40 µM doxorubicin at 37 °C for 1 h. The cell suspensions were centrifuged on 
4500 rpm for 5 min and washed twice with ice-cold PBS. After resuspending the cells in 
water, doxorubicin was extracted (using 60% ethanol +0.3 M HCl) and quantified by high 
performance liquid chromatography (HPLC). For the toxicity assay, the cell suspensions 
were also centrifuged on 4500 rpm for 5 min and washed twice in serum-free medium. 
The cells were cultured for 48 h at 37 °C using 96 well plates (105 cell/0.15ml per well) in 
serum supplemented medium. Cell proliferation was evaluated by the above mentioned 
MTT test. Statistical analysis was performed by using an ANOVA model. 
3.9 In vivo studies 
 
3.9.1 In vivo doxorubicin accumulation 
DBA/2 mice were anesthetized and injected subcutaneously with 4 x 106 cells of the 
parental or transfected L 5178 Y cells. Tumours were allowed to grow to ca 0.5 cm 
diameter, after which the animals were treated once with various regimens of TBN (10 
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and 50 mg/kg) or vehicle, and doxorubicin (10 mg/kg) or vehicle, administered either i.p. 
or i.v. via a lateral tail vein. Tumours were excised 24 h after i.p. or i.v. administration 
and stored at -20°C until extraction and HPLC analysis. 
3.9.2 Sample extraction and doxorubicin quantification 
The amount of doxorubicin in frozen tumour quantified. Samples were thawed and 
thoroughly homogenized. Dilutions of the homogenate were prepared in water (100 
mg/mL), and 200 µL aliquots were diluted with an equal volume of 6% (w/v) borate buffer 
(pH 9.5) and 50 µL internal standard (daunorubicin) working solution. After vortexing, the 
analytes were extracted with 1 mL of a chloroform/propanol mixture (4:1, v/v) by mixing 
for 5 min, followed by centrifugation for 10 min at 4°C (6000 rpm). The aqueous layer 
and the pellet were removed by suction, and the isolated organic layer evaporated using 
a Speed-Vacuum system (Reciprotor, Denmark) at 43°C. The residue was reconstituted 
in 75 µL of acetonitrile-tetrahydrofuran (40:1, v/v), vortexed for 20 s and then sonicated 
for 5 min. After adding 125 µL acidified water (pH 2.05), a 20 µL aliquot was analyzed by 
LC.  
Statistical analysis. Statistical analysis of the data was performed with Graphpad Prism 
2.01 (Graph Pad Software, San Diego, CA, USA). 
3.10 Apoptosis assays 
 
3.10.1   Flow-cytometric assay for apoptosis 
The cells were adjusted to a density of 2x105/mL and were distributed in 1.0 mL aliquots 
into microcentrifuge tubes. The apoptosis inducer 12H-benzo[α]phenothiazine (M627) 
was added to the samples as a positive control at a final concentration of 5 or 25 µg/mL. 
In the cases of control cultures, 10 µL DMSO was added. The compounds used for 
treatment was added to the samples at a final concentration of 2 or 10 µg/mL. After 
incubation for 24 h at 37 °C, the cells were transferred from a 24-well plate into 
Eppendorf centrifuge tubes, centrifuged and washed with PBS, and resuspended in 195 
µL binding buffer. The samples were mixed and centrifuged and supernatant was 
removed from each tube. 5 µL Annexin V was added to the tubes. Controls without 
Annexin V were also prepared. The samples and controls were incubated at room 
temperature for 10 min in the dark, then centrifuged, washed with PBS, and 
resuspended in 190 µL binding buffer. Before the measurement of fluorescence activity, 
10 µL of 20 µg/mL PI was added to the samples and the apoptosis of the cells was next 
investigated. The fluorescence activity (FL-1 and FL-2) of the cells was measured and 
analysed on a Beckton Dickinson FACScan instrument.  
 
3.10.2 Ethidium bromide and acridine orange (EB/AO) staining for 
apoptosis 
Staining with EB/AO was carried out in a 96-well plate format after 24 h of treatment in 
order to visualize the basic morphological events. Plates were centrifuged at 1000 rpm 
for 5 min, and 8 µL of staining solution (0.1 mg/mL for both AO and EB in PBS) was 
added to each well. After 10 min, the cells were washed with PBS, and the cells were 
evaluated with a Nikon Eclipse inverted microscope. Pictures were taken with a Nikon 
Coopix 4500 digital camera (Nikon, Tokyo, Japan). 
 
3.11  Anti-promotion experiments 
One-day-old A549 cultures on the coverslips were infected with “Towne” strain of CMV at 
a multiplicity of infection of 2.4. The infected A549 cultures were centrifuged for 60 min at 
1200 rpm in a Heraeus, Megafuge 1.0 at room temperature and then incubated for 1h at 
37 ºC. The unabsorbed virus was removed and the cells were washed three times with 
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serum-free medium. After washing, the cells were overlayed with medium containing the 
appropriate concentration of a compound or DMSO. After 48 hours incubation, the cells 
were washed twice with cold PBS and fixed with cold acetone: ethanol for 20 min at –
20 ºC. The fixed cells were stored at –20 ºC until immunofluorescence assays were 
performed. 
Human CMV IE1-72 antigen was detected in the nuclei of infected cells by MAB810 and 
fluorescein isothiocyanate (FITC)-conjugated rabbit anti-mouse IgG. The number of IE 
antigen-positive cells was counted in 30 microscopic fields containing 400 cells for each 
sample. The frequency of IE antigen-expressing cells in the treated cultures is shown as 
a percentage of the control.  
 
 
4 .  RESULTS AND DISCUSSION 
 
4.1 Antiproliferative and cytotoxic effect of tested compounds 
In the first stage of study the antiproliferative and cytotoxic property of various 
compounds were determined of possible MDR modifiers. The inhibitory dose fifty (ID50) 
are essential data to design combination experiments with several anticancer drugs. The 
complex effect on cell proliferation and viability may depend on the chemical structure of 
each derivatives and sensitivity of cell lines. 
 
4.2 Reversal of MDR1 by flow-cytometric assay 
The first part of this thesis was focused on the inhibition of MDR through inhibition of the 
MDR P-glycoprotein in various cell lines. Six groups of compound were involved in the 
P-gp efflux pump inhibitory studies: cinnamylidene ketones; 1,4-diphenyl-1,4-
dihydropyridine derivatives; phenothiazines; HSP90 inhibitor peptide derivatives; Betti 
base derivative of Tylosin and Euphorbia diterpenes. 
Among the tested cinnamylidene ketones, 2-(2-methoxycinnamylidene)indan-1-one 
(4), 2-cinnamylidene-3,4-dihydro-2H-naphthalen-1-one (7), 2-(2-methoxycinnamylidene)-
3,4-dihydro-2H-naphthalen-1-one (8),  6-cinnamylidene-6,7,8,9-
tetrahydrobenzocyclohepten-5-one (10) and 6-(2-methoxycinnamylidene)-6,7,8,9-
tetrahydrocyclohepten-5-one (11), display marked effectivity for the reversal of the MDR 
on human mdr1 gene-transfected mouse lymphoma cells and human colon cancer cell 
line (COLO 320). In the case of the COLO 320 cells, which express the mdr1 gene, the 
degree of Rhodamin 123 accumulation was lower than on the artificially constructed 
extremely sensitive mouse lymphoma cells, in which P-gp is overexpressed. This means 
that the effectivity of the reversal compounds also depends on the “type” of cancer cells, 
which express more or less vulnerable P-gp.  
 
Most of the 1,4-diphenyl-1,4-dihydropyridine derivatives considered as potent 
inhibitors of multidrug resistance. The 1,4-dihydropyridine heterocyclic rings is a 
common feature of various bioactive compounds, such as vasodilator, bronchodilator, 
antitubercular agents and more recently MDR modulators and antitumour agents. 1,4-
Dihydropyridines are well known as Ca2+ channel blockers and as drugs for the 
treatment of cardiovascular diseases, including hypertension. Some dihidropyridines at 
the higher concentrations used were found to be toxic, but at low doses most of the 
derivatives were able to increase the R123 accumulation. 
 
Phenothiazines, apart from their wide range of biological activity have been described as 
effective MDR modifiers.  
The tested phenothiazines were moderately active resistance modulators, especially in 
the low concentration. Two of the phenothiazine derivatives namely perphenazine and 
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prochlorperazine dimaleate proved to be effective inhibitors of Rhodamin efflux. The 
higher concentration, appeared cytotoxic, however, this effect was more profoundly 
accentuated in MDR1-expressing mouse T-cell lymphoma cell line than in COLO 320 
cell line. Methotripromazine maleate and prochlorperazine dimaleate caused 
decreased cell survival of the two cell lines studied. Similarly, trifluoropromazine 
hydrochloride was toxic. It is reported, that phenothiazine hydrochlorides are able to 
modify cell membrane properties by disorganization of the phospholipids and 
translocation of antitumour drug complexes through the membrane. On the other hand, 
the same ability could also benefit in modulation of MDR. Actually, if the drug 
concentration was reduced, obviously it would behave as an effective MDR inhibitor and 
did not cause cell death.  
 
Heat shock protein 90 (Hsp90) inhibitor peptides arrests the growth of cancer cells. 
D-Trp-Phe-D-Trp-Leu-AMB (1), which has a relatively high apolar character, and its 
succinylated derivative, Suc-D-Trp-Phe-D-Trp-Leu-AMB (4) which is slightly more water 
soluble demonstrated the highest fluorescence activity ratios. Interestingly, replacing the 
N-terminal D-Trp of 1 by D-Tyr to obtain D-Tyr-Phe-D-Trp-Leu-AMB (5) caused a 
dramatic change in the fluorescence activity ratio, indicating that the indole side-chain at 
this position is indispensable for the biological effect, and for the reversal of MDR of 
cancer cells. The activity of the peptide derivatives in reversing the MDR did not depend 
upon the length of the peptide chain: rather, it depended on the stacking ability of 
tryptophan, and the tetrapeptide structure proved best from this respect.  In the in vivo 
model experiments, it is reported that these peptides inhibited tumour growth in nude 
mice bearing the xenografts. 
 
In order to get better insight into structure activity relationship in vitro P-gp inhibitory 
effects of N-Tylosil-1-α-amino-(3-bromophenyl)-methyl-2-naphtanol (TBN) and its 
precursor moieties (tylosin and betti base) were also studied. TBN treatment was 
resulted significantly higher activity in P-gp inhibition than its two precursor moiety. This 
finding also suggests that the molar weight and lipophilicity of compound has a crucial 
role in P-gp substrate specifity and/or inhibition. 
 
Besides the presence of highly skin-irritant compounds, Euphorbia species are of 
further considerable interest owing to a large diversity of structurally unique and non-
irritant jatrophane and lathyrane diterpenoid constituents, which have been considered to 
be potent modulators of MDR. 
Three of the tested diterpene derivatives (6, 8 and 9) displayed a significant 
concentration-dependent effect in inhibiting the efflux pump activity on the COLO 320 
cell line.  
 
4.3 Interaction of resistance modifier with anticancer drugs 
Two of the tested compounds, namely, 2-(2-methoxycinnamylidene) indan-1-one (4) and 
2-(2-methoxycinnamylidene)-3,4-dihydro-2H-naphthalen-1-one (8) were able to enhance 
the antiproliferative activity of doxorubicin in a synergistic way. Similar studies illustrated 
that combined application of above mentioned two compounds with paclitaxel, docetaxel 
or vincristine exerted significant antiproliferative effects on the resistance sublines of 
MCF7.  
 
The high anti-MDR potency of selected dihydropyridines (DL4, DL12, DL13 and DP89) 
were also very effective in combination with doxorubicin.  
 
Significant synergism was observed in vitro combination of TBN and doxorubicin and/or 
vincristine on mouse lymphoma cell line. 
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The most effective synergistic effect was found between Euphorbia diterpene 8 and 
epirubicin. The strong activity of this derivative can be explained by its high lipophilicity, 
but other parameters, such as the presence of functional groups, may also be involved in 
the synergistic effect and in the interaction with P-gp. 
On comparison of the efficacies of compounds 7 and 8, it can be presumed that the 
presence of a hydroxy group is favourable as concerns the antiproliferative activity in 
combination with epirubicin. Although compound 9, significantly increased the R123 
accumulation in COLO 320 cells, in combination with epirubicin it had no antiproliferative 
effect on the tested cell line. The differences between the dose-dependent 
antiproliferative and the MDR-reversal effects of studied derivatives can be 
consequences of the various experimental procedures, including the different incubation 
times, and possible metabolisms of compounds. 
 
4.4 Cellular accumulation and cytotoxicity of doxorubicin in mouse 
lymphoma cell line in vitro  
In the absence of TBN, More than double difference was found between doxorubicin 
accumulation of the resistant and non-resistant cells. TBN treatment was able to restore 
the sensitivity of resistant cell line to doxorubicin, whereas it had no significant effect on 
the accumulation of non-resistant ones. Linear correlation was found between the 
toxicity and accumulation of doxorubicin however the cells were exposed to higher 
concentration of doxorubicin in short time incubation.  
 
4.5 In vivo doxorubicin accumulation study in mouse MDR cells 
The in vitro activity of TBN was confirmed in further in vivo efficacy studies. The 
combination of doxorubicin with TBN increased the doxorubicin concentration in the 
tumours compared with doxorubicin alone using DBA/2 mice bearing syngeneic 
L 5178 Y tumours. Independently from doxorubicin administration (i.v. or i.p.), TBN 
treatment was able to restore the doxorubicin sensitivity of resistant tumours.  
4.6 Apoptosis induction of some resistance modifiers 
Many classes of antitumour drugs, including naturally occurring and pharmaceutical 
compounds, induce apoptosis in cancer cell. 
In our study the tested compounds (cinnamylidene 4 and 8, dihydropyridine 12 and 
Euphorbia diterpene 8) were able to induce moderate apoptosis in human mdr1 gene-
transfected mouse lymphoma cell line. The most promising apoptosis inducer was the 
dihydropyridine substituted compound 13, however, the levels of total apoptosis were 
much lower in every case than positive control 12H-benzo[α]phenothiazine (M-627). The 
annexin V positivity of treated-cells by various compounds could be a consequence of 
the structural alteration in cell membrane, which results in the translocation of 
phosphatidylserine molecules from the inside to the outer surface of the membrane. 
 
The ethidium bromide and acridine orange (EB/AO) staining of the HeLa cells 
(monolayer) allowed the identification of live, apoptotic and necrotic cells, in situ. Even at 
a lower concentration of diterpene 8 (2 µg/mL), treatment of HeLa cells with possible 
MDR modifiers led to the typical morphological features of apoptosis. 
 
4.7 Anti-promotion effect of plant derivatives 
The human CMV was used in a modified in vitro model for characterizing lathyrane 
compounds with antipromotion effect on human lung cancer cells (A549). All the 
compounds, except latilagascene D, decreased IE antigen expression of CMV.   
The structures of the six studied compounds differ in the substitution pattern of ring “A“ 
having compound 5 also a different substitution at C-20 where the methyl group is 
 11 
oxidized, having been replaced by a -CH2OH. This structural feature appears to be 
important justifying the activity difference between latilagascene D (4) and latilagascene 
E (5) which showed the highest activity as anti-promoters. The comparison of the activity 
of compounds 4 and 1, whose structures differ only at the ester group at C-16, suggests 
that the presence of the benzoyl moiety in the former has a negative action in the 
inhibitory effect.  
 
5 .  NEW STATEMENTS 
 
I. Based on the antiproliferative or cytotoxic effect differences were found between 
sensitive and MDR tumour cells. 
II. During my Ph.D study several groups of compounds were identified as MDR 
modulators. 
A majority of the tested cinnamylidene derivatives were able to increase the R123 
accumulation in human mdr1 gene-transfected mouse lymphoma cell line (L 5178 
Y) and also in human colon cancer cells (COLO 320). The MDR-reversing effect of 
tested of cinnamylidenes were markedly lower in COLO 320 cells as compared with 
L 5178 Y cell line. The reason for this phenomenon could be the fact that P-
glycoprotein expression in COLO 320 cell line is lower than in L 5178 Y cells. 
Numerous tested 1,4-diphenyl-1,4-dihydropyridine derivatives reversed the 
MDR of tumour cells more effectively than the reference compound, verapamil.  
Two of the phenothiazine derivatives namely perphenazine and 
prochlorperazine dimaleate proved to be effective inhibitors of rhodamin efflux. 
Other tested phenothiazine derivatives also modulated intracellular drug 
accumulation in resistant cell lines. 
Among the synthetic HSP90 inhibitor peptide derivatives two of the strongly 
hydrophobic compounds (compound 1 and 4) were the most potent in MDR 
reversal. 
TBN (N-tylosil-1-α-amino-(3-bromophenyl)-methyl-2-naphthol), and not the 
individual Betti-base and tylosin moieties, is able to increase the cellular uptake of 
the fluorescent P-gp substrate Rhodamin 123 in human mdr1 gene transfected 
mouse T-cell lymphoma drug resistant cell line, and fully reversed the cellular 
resistance against doxorubicin. 
It seems that the effect of Euphorbia diterpenes on MDR reversal effect of tumour 
cells depends on the chemical structure. The presence of hydroxy group instead of 
peracylation is favourable on COLO 320 cells. 
III.  Generality, the newly identified MDR modifiers were able to enhance the 
antiproliferative activity of selected anticancer drugs (e. g. doxorubicin, paclitaxel 
and vincristine) in a synergistic or additive way in vitro on MDR cells. 
The in vivo results shown, that co-administration of TBN with doxorubicin 
significantly increased the antitumour activity of doxorubicin in DBA/2 mice.  
IV. As an alternative way of antitumour effect, apoptosis induction of resistance 
modifiers was studied.  
Dihydropyridine 13 was the most promising apoptosis inducer on L 5178 Y cells 
during the 1 hour incubation. 
Typical apoptotic markers were observed after a 24 h treatment with the tested 
jatrophane derivative 8 by staining with ethidium bromide and acridine orange on 
HeLa cells. 
V.  As a model for prevention of cancer progression by CMV infection, the antitumour-
promotion effects of some resistance modifiers were studied. All the six 
macrocyclic lathyrane-type diterpenoids, could reduced the promotion in vitro, 
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except latilagascene D, decreased IE-antigen expression of CMV to prevent 
progression of tumour malignancy. 
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